Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company in the health and wellness sector, has officially completed its acquisition of Bio Legacy Evaluative Group, formerly known as Menlo Health. This all-stock deal, valued at $1.5 million in Preferred D shares, was finalized on July 31, 2025. The acquisition signifies Branded Legacy's strategic expansion into the biotech and medical devices industry, aiming to tackle pressing global health issues such as the addiction epidemic and inefficiencies in vaccine distribution.
Under the leadership of CEO Amin Janmohamed, Bio Legacy Evaluative Group brings to the table a patented all-in-one intranasal naloxone device. This innovation targets a rapidly growing market, projected to expand from $371 million in 2022 to over $1.16 billion by 2032. Additionally, Bio Legacy's technology for nasal delivery of vaccines and cold-chain therapies presents a significant opportunity to revolutionize how these critical health solutions are administered worldwide.
The terms of the acquisition include performance-based conversion milestones, a two-year lock-up period, and a commitment to invest $1 million in research and development following the company's uplisting to OTCQB. This move not only underscores Branded Legacy's commitment to innovation and quality but also its dedication to creating sustainable value for its shareholders while making a tangible impact on global health challenges.
For further details on this acquisition, visit https://ibn.fm/U7eSy. More information about Branded Legacy Inc. can be found at https://BrandedLegacy.com.
